420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study

• Mario Sznol,
• Adi Diab,
• Brendan Curti,
• Igor Puzanov,
• Gregory Daniels,
• Jonathan Zalevsky,
• Ute Hoch,
• Mary Tagliaferri,
• Michael Hurwitz,
• Scott Tykodi,
• Michele Maio,
• Sekwon Jang,
• Tuan Nguyen,
• Wei Lin,
• Karl Lewis,
• Alexander Spira,
• Ewa Kalinka,
• Daniel Cho,
• Shanhong Guan,
• Erika Puente,
• Sue Currie

Affiliations

Mario Sznol

4Yale University, New Haven, CT, USA

Adi Diab

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Brendan Curti

1 Providence Cancer Institute, Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA

Igor Puzanov

9Roswell Park Cancer Institute, Buffalo, NY, USA

Gregory Daniels

3University of California, La Jolla, CA, USA

Jonathan Zalevsky

7Nektar Therapeutics, San Francisco, CA, USA

Ute Hoch

12Nektar Therapeutics, San Francisco, CA, USA

Mary Tagliaferri

7Nektar Therapeutics, San Francisco, CA, USA

Michael Hurwitz

13Yale School of Medicine, New Haven, CT, USA

Scott Tykodi

2University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Michele Maio

4Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy

Sekwon Jang

7Inova Fairfax Hospital, Fairfax, VA, USA

Tuan Nguyen

12Nektar Therapeutics, San Francisco, CA, USA

Wei Lin

7Nektar Therapeutics, San Francisco, CA, USA

Karl Lewis

6University of Colorado, Aurora, CO, USA

Alexander Spira

10Virginia Cancer Specialists, Fairfax, VA, USA

Ewa Kalinka

8Santa Familia Medical Institute, Lodz, Poland

Daniel Cho

11NYU Medical Oncology Associates, New York, NY, USA

Shanhong Guan

12Nektar Therapeutics, San Francisco, CA, USA

Erika Puente

12Nektar Therapeutics, San Francisco, CA, USA

Sue Currie

12Nektar Therapeutics, San Francisco, CA, USA